Technische Universität München
How do bacteria build up natural products? X-ray structure analysis gives detailed insights into molecular factory
TECHNICAL UNIVERSITY OF MUNICH
Corporate Communications Center
phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de
This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36121/
High resolution images: https://mediatum.ub.tum.de/1552301
NEWS RELEASE
How do bacteria build up natural products?
X-ray structure analysis gives detailed insights into molecular factory
The active agents of many drugs are natural products, so called because often only microorganisms are able to produce the complex structures. Similar to the production line in a factory, large enzyme complexes put these active agent molecules together. A team of the Technical University of Munich (TUM) and the Goethe University Frankfurt has now succeeded in investigating the basic mechanisms of one of these molecular factories.
Many important drugs such as antibiotics or active agents against cancer are natural products which are built up by microorganisms for example bacteria or fungi. In the laboratory, these natural products can often be not produced at all or only with great effort. The starting point of a large number of such compounds are polyketides, which are carbon chains where every second atom has a double bound to an oxygen atom.
In a microbial cell such as in the Photorhabdus luminescens bacterium, they are produced with the help of polyketide synthases (PKS). In order to build up the desired molecules step by step, in the first stage of PKS type II systems, four proteins work together in changing "teams".
In a second stage, they are then modified to the desired natural product by further enzymes. Examples of bacterial natural products which are produced that way are, inter alia, the clinically used Tetracyclin antibiotics or Doxorubicin, an anti-cancer drug.
Interdisciplinary cooperation
While the modified steps of the second stage are well studied for many active agents, there have up to now hardly been any insights into the general functioning of the first stage of these molecular factories where the highly reactive polyketide intermediate product is bound to the enzyme complex and protected so that it cannot react spontaneously.
This gap is now closed by the results of the cooperation between the working groups of Michael Groll, professor of biochemistry at the Technical University of Munich, and Helge Bode, professor of molecular biotechnology at Goethe University Frankfurt, which are published in the renowned scientific journal Nature Chemistry.
Findings inspire to new syntheses of active agents
"In the context of this work, we were for the first time able to analyze complexes of the different partner proteins of type II polyketide synthase with the help of X-ray structure analysis and now understand the complete catalytic cycle in detail," Michael Groll explains.
"Based on these findings, it will be possible in the future to manipulate the central biochemical processes in a targeted manner and thus change the basic structures instead of being restricted to the decorating enzymes," Helge Bode adds.
Although it is a long way to develop improved antibiotics and other drugs, both groups are optimistic that now also the structure and the mechanism of the missing parts of the molecular factory can be explained. "We already have promising data of the further protein complexes," says Maximilian Schmalhofer, who was involved in the study as a doctoral candidate in Munich.
Publication:
Alois Bräuer, Qiuqin Zhou, Gina L.C. Grammbitter, Maximilian Schmalhofer, Michael Rühl, Ville R.I. Kaila, Helge B. Bode und Michael Groll:
Structural snapshots of the minimal PKS system responsible for octaketide biosynthesis,
Nature Chemistry 06.07.2020 - DOI: 10.1038/s41557-020-0491-7
Link: https://www.nature.com/articles/s41557-020-0491-7
More information:
The work was supported with funds of the Deutsche Forschungsgemeinschaft (DFG) in the context of SPP 1617, SFB 1035 and the cluster of excellence Center for Integrated Protein Science Munich (CIPSM) and the LOEWE focus MegaSyn of the State of Hesse. X-ray structure data were measured at the Paul Scherrer Institute in Villigen (Switzerland). The Swedish National Infrastructure for Computing provided computing time for the theoretical modeling.
High resolution images:
https://mediatum.ub.tum.de/1552301
Contact:
Prof. Dr. Michael Groll
Professorship of Biochemistry
Technical University of Munich
Lichtenbergstr. 4, 85748 Garching, Germany
Tel.: +49 89 289 13360 - michael.groll@tum.de
Web: https://www.department.ch.tum.de/biochemie/
Prof. Dr. Helge Bode
Professorship of Molecular Biotechnology
Goethe-University Frankfurt
Campus Riedberg
Tel.: +49 69 798 29557 - e-mail: h.bode@bio.uni-frankfurt.de
Web: https://www.goethe-university-frankfurt.de/60271232/Abt__Bode
The Technical University of Munich (TUM) is one of Europe's leading research universities, with around 600 professors, 43,000 students, and 10,000 academic and non-academic staff. Its focus areas are the engineering sciences, natural sciences, life sciences and medicine, combined with economic and social sciences. TUM acts as an entrepreneurial university that promotes talents and creates value for society. In that it profits from having strong partners in science and industry. It is represented worldwide with the TUM Asia campus in Singapore as well as offices in Beijing, Brussels, Cairo, Mumbai, San Francisco, and São Paulo. Nobel Prize winners and inventors such as Rudolf Diesel, Carl von Linde, and Rudolf Mößbauer have done research at TUM. In 2006, 2012 and 2019 it won recognition as a German "Excellence University." In international rankings, TUM regularly places among the best universities in Germany. www.tum.de